Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device (LVIS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01541254 |
Recruitment Status
:
Completed
First Posted
: February 29, 2012
Results First Posted
: September 15, 2014
Last Update Posted
: September 15, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Intracranial Aneurysms | Device: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.) | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Feasibility Study of the MicroVention,Inc.(LVIS™) Neurovascular Self-Expanding Retrievable Stent System in the Treatment of Wide-Necked Intracranial Artery Aneurysms |
Study Start Date : | March 2012 |
Actual Primary Completion Date : | June 2013 |
Actual Study Completion Date : | June 2013 |
Arm | Intervention/treatment |
---|---|
Single Arm
Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
|
Device: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
Other Name: Low-profile Vizualized Intraluminal Support Device
|
- Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks) [ Time Frame: 6 months ± 4 weeks ]Imaging from each subject to be reviewed by an independent core lab who will be comparing with baseline and post procedure images.
- Safety Measures as Any Major Stroke or Death Within 30 Days, or Major Ipsi-lateral Stroke or Neurological Death Within 6 Months [ Time Frame: 30 days-6 months ]A major stroke is defined as a new neurological event that persists for >24 hours and results in a ≥ 4 point increase in the National Institutes of Health Stroke Scale (NIHSS) score compared to baseline or compared to any subsequent lower score.
- Parent Artery Patency Measured Angiographically at 6 Months [ Time Frame: 6 months ]To be assessed by Independent Core Lab.
- Successful Delivery of the LVIS™ Device Measures by Technical Success [ Time Frame: 24 hours ]Technical success being defined as: access to the lesion, successful deployment of the LVIS™ device.
- Significant Stenosis(>50%) of the Treated Artery at 6 Months [ Time Frame: 6 months ]Parent Artery will be measured baseline and compared at 6 months post procedure per review by the Independent Core Lab.
- Stent Migration at 6 Months [ Time Frame: 6 months ]Angiographic images will be comparing post procedure sent position to 6 months
- Device and Procedure Related Serious Adverse Events [ Time Frame: Day 1-6months(± 4 months) ]All Serious Adverse events will be reported per protocol
- Unplanned Embolization Coiling Within 6 Months [ Time Frame: Day 1-6 months ]If the target lesion(aneurysm)treated needed further embolization within 6 months of initial treatment(detected during follow up or unscheduled visit ),data will be recorded and analyzed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject whose age is between 18 and 80 years old
- Subject with unruptured wide neck, saccular,intracranial aneurysm, < 20mm maximum diameter in any plane ( wide neck defined as neck width ≥ 4mm or dome to-neck ratio < 2).
- Subject's aneurysm arises from a parent vessel with a diameter of ≥ 2.5m and ≤ 4.5mm.
- Subject or his/her legally authorized representative understands the nature of the procedure and provides signed informed consent form.
- Subject is willing to return to the investigational site for the 30- day and 6-month follow-up evaluations
Exclusion Criteria:
- Subject who presents with ruptured aneurysm, unless rupture occured 30 days or more prior to screening.
- Subject who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region.
- Subject with an International Normalized Ratio (INR)≥ 1.5
- Subject with serum creatinine level >2mg/dl at time of enrollment
- Subject with known allergies to nickel-titanium metal
- Subject with known allergies to aspirin, heparin, ticlopidine, or clopidogrel
- Subject with a life threatening allergy to contrast(unless treatment for allergy is tolerated)
- Subject who has a known cardiac disorder, likely to be associated with cardioembolic symptoms such as atrial fibrillation
- Subject with any condition which in the opinion of the treating physician would place the subject at a high risk of embolic stroke
- Subject who is currently participating in another clinical research study
- Subject who has had a previous intracranial stenting procedure associated with the target aneurysm
- Subject who is unable to complete the required follow-up
- Subject who is pregnant or breastfeeding
- Subject who has participated in a drug study within the last 30 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01541254
United States, New York | |
Albany Medical College | |
Albany, New York, United States, 12208 | |
Stony Brook University Medical Center | |
Stony Brook, New York, United States, 11794 | |
United States, Pennsylvania | |
Thomas Jefferson Hospital | |
Philadelphia, Pennsylvania, United States, 19107 | |
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29425 | |
United States, Texas | |
UT Southwestern | |
Dallas, Texas, United States, 75390 | |
Methodist Hospital | |
Houston, Texas, United States, 77030 |
Principal Investigator: | David Fiorella, M.D., Ph.D. | Stony Brook University Medical Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Microvention-Terumo, Inc. |
ClinicalTrials.gov Identifier: | NCT01541254 History of Changes |
Other Study ID Numbers: |
G110014 |
First Posted: | February 29, 2012 Key Record Dates |
Results First Posted: | September 15, 2014 |
Last Update Posted: | September 15, 2014 |
Last Verified: | September 2014 |
Keywords provided by Microvention-Terumo, Inc.:
intracranial aneurysm wide-neck saccular endovascular treatment |
coil embolization stent bare platinum |
Additional relevant MeSH terms:
Aneurysm Intracranial Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |